House modifications for preventing malaria.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
20 01 2021
Historique:
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 20 2 2021
Statut: epublish

Résumé

Despite being preventable, malaria remains an important public health problem. The World Health Organization (WHO) reports that overall progress in malaria control has plateaued for the first time since the turn of the century. Researchers and policymakers are therefore exploring alternative and supplementary malaria vector control tools. Research in 1900 indicated that modification of houses may be effective in reducing malaria: this is now being revisited, with new research now examining blocking house mosquito entry points or modifying house construction materials to reduce exposure of inhabitants to infectious bites. To assess the effects of house modifications on malaria disease and transmission. We searched the Cochrane Infectious Diseases Group Specialized Register; Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (PubMed); Embase (OVID); Centre for Agriculture and Bioscience International (CAB) Abstracts (Web of Science); and the Latin American and Caribbean Health Science Information database (LILACS), up to 1 November 2019. We also searched the WHO International Clinical Trials Registry Platform (www.who.int/ictrp/search/en/), ClinicalTrials.gov (www.clinicaltrials.gov), and the ISRCTN registry (www.isrctn.com/) to identify ongoing trials up to the same date. Randomized controlled trials, including cluster-randomized controlled trials (cRCTs), cross-over studies, and stepped-wedge designs were eligible, as were quasi-experimental trials, including controlled before-and-after studies, controlled interrupted time series, and non-randomized cross-over studies. We only considered studies reporting epidemiological outcomes (malaria case incidence, malaria infection incidence or parasite prevalence). We also summarised qualitative studies conducted alongside included studies. Two review authors selected eligible studies, extracted data, and assessed the risk of bias. We used risk ratios (RR) to compare the effect of the intervention with the control for dichotomous data. For continuous data, we presented the mean difference; and for count and rate data, we used rate ratios. We presented all results with 95% confidence intervals (CIs). We assessed the certainty of evidence using the GRADE approach. Six cRCTs met our inclusion criteria, all conducted in sub-Saharan Africa; three randomized by household, two by village, and one at the community level. All trials assessed screening of windows, doors, eaves, ceilings or any combination of these; this was either alone, or in combination with eave closure, roof modification or eave tube installation (a "lure and kill" device that reduces mosquito entry whilst maintaining some airflow). In two trials, the interventions were insecticide-based. In five trials, the researchers implemented the interventions. The community implemented the interventions in the sixth trial. At the time of writing the review, two of the six trials had published results, both of which compared screened houses (without insecticide) to unscreened houses. One trial in Ethiopia assessed screening of windows and doors. Another trial in the Gambia assessed full screening (screening of eaves, doors and windows), as well as screening of ceilings only. Screening may reduce clinical malaria incidence caused by Plasmodium falciparum (rate ratio 0.38, 95% CI 0.18 to 0.82; 1 trial, 184 participants, 219.3 person-years; low-certainty evidence; Ethiopian study). For malaria parasite prevalence, the point estimate, derived from The Gambia study, was smaller (RR 0.84, 95% CI 0.60 to 1.17; 713 participants, 1 trial; low-certainty evidence), and showed an effect on anaemia (RR 0.61, 95% CI 0.42, 0.89; 705 participants; 1 trial, moderate-certainty evidence). Screening may reduce the entomological inoculation rate (EIR): both trials showed lower estimates in the intervention arm. In the Gambian trial, there was a mean difference in EIR between the control houses and treatment houses ranging from 0.45 to 1.50 (CIs ranged from -0.46 to 2.41; low-certainty evidence), depending on the study year and treatment arm. The Ethiopian trial reported a mean difference in EIR of 4.57, favouring screening (95% CI 3.81 to 5.33; low-certainty evidence). Pooled analysis of the trials showed that individuals living in fully screened houses were slightly less likely to sleep under a bed net (RR 0.84, 95% CI 0.65 to 1.09; 2 trials, 203 participants). In one trial, bed net usage was also lower in individuals living in houses with screened ceilings (RR 0.69, 95% CI 0.50 to 0.95; 1 trial, 135 participants). Based on the two trials published to date, there is some evidence that screening may reduce malaria transmission and malaria infection in people living in the house. The four trials awaiting publication are likely to enrich the current evidence base, and we will add these to this review when they become available.

Sections du résumé

BACKGROUND
Despite being preventable, malaria remains an important public health problem. The World Health Organization (WHO) reports that overall progress in malaria control has plateaued for the first time since the turn of the century. Researchers and policymakers are therefore exploring alternative and supplementary malaria vector control tools. Research in 1900 indicated that modification of houses may be effective in reducing malaria: this is now being revisited, with new research now examining blocking house mosquito entry points or modifying house construction materials to reduce exposure of inhabitants to infectious bites.
OBJECTIVES
To assess the effects of house modifications on malaria disease and transmission.
SEARCH METHODS
We searched the Cochrane Infectious Diseases Group Specialized Register; Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (PubMed); Embase (OVID); Centre for Agriculture and Bioscience International (CAB) Abstracts (Web of Science); and the Latin American and Caribbean Health Science Information database (LILACS), up to 1 November 2019. We also searched the WHO International Clinical Trials Registry Platform (www.who.int/ictrp/search/en/), ClinicalTrials.gov (www.clinicaltrials.gov), and the ISRCTN registry (www.isrctn.com/) to identify ongoing trials up to the same date.
SELECTION CRITERIA
Randomized controlled trials, including cluster-randomized controlled trials (cRCTs), cross-over studies, and stepped-wedge designs were eligible, as were quasi-experimental trials, including controlled before-and-after studies, controlled interrupted time series, and non-randomized cross-over studies. We only considered studies reporting epidemiological outcomes (malaria case incidence, malaria infection incidence or parasite prevalence). We also summarised qualitative studies conducted alongside included studies.
DATA COLLECTION AND ANALYSIS
Two review authors selected eligible studies, extracted data, and assessed the risk of bias. We used risk ratios (RR) to compare the effect of the intervention with the control for dichotomous data. For continuous data, we presented the mean difference; and for count and rate data, we used rate ratios. We presented all results with 95% confidence intervals (CIs). We assessed the certainty of evidence using the GRADE approach.
MAIN RESULTS
Six cRCTs met our inclusion criteria, all conducted in sub-Saharan Africa; three randomized by household, two by village, and one at the community level. All trials assessed screening of windows, doors, eaves, ceilings or any combination of these; this was either alone, or in combination with eave closure, roof modification or eave tube installation (a "lure and kill" device that reduces mosquito entry whilst maintaining some airflow). In two trials, the interventions were insecticide-based. In five trials, the researchers implemented the interventions. The community implemented the interventions in the sixth trial. At the time of writing the review, two of the six trials had published results, both of which compared screened houses (without insecticide) to unscreened houses. One trial in Ethiopia assessed screening of windows and doors. Another trial in the Gambia assessed full screening (screening of eaves, doors and windows), as well as screening of ceilings only. Screening may reduce clinical malaria incidence caused by Plasmodium falciparum (rate ratio 0.38, 95% CI 0.18 to 0.82; 1 trial, 184 participants, 219.3 person-years; low-certainty evidence; Ethiopian study). For malaria parasite prevalence, the point estimate, derived from The Gambia study, was smaller (RR 0.84, 95% CI 0.60 to 1.17; 713 participants, 1 trial; low-certainty evidence), and showed an effect on anaemia (RR 0.61, 95% CI 0.42, 0.89; 705 participants; 1 trial, moderate-certainty evidence). Screening may reduce the entomological inoculation rate (EIR): both trials showed lower estimates in the intervention arm. In the Gambian trial, there was a mean difference in EIR between the control houses and treatment houses ranging from 0.45 to 1.50 (CIs ranged from -0.46 to 2.41; low-certainty evidence), depending on the study year and treatment arm. The Ethiopian trial reported a mean difference in EIR of 4.57, favouring screening (95% CI 3.81 to 5.33; low-certainty evidence). Pooled analysis of the trials showed that individuals living in fully screened houses were slightly less likely to sleep under a bed net (RR 0.84, 95% CI 0.65 to 1.09; 2 trials, 203 participants). In one trial, bed net usage was also lower in individuals living in houses with screened ceilings (RR 0.69, 95% CI 0.50 to 0.95; 1 trial, 135 participants).
AUTHORS' CONCLUSIONS
Based on the two trials published to date, there is some evidence that screening may reduce malaria transmission and malaria infection in people living in the house. The four trials awaiting publication are likely to enrich the current evidence base, and we will add these to this review when they become available.

Identifiants

pubmed: 33471371
doi: 10.1002/14651858.CD013398.pub3
pmc: PMC8642787
doi:

Substances chimiques

Insecticides 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD013398

Subventions

Organisme : Medical Research Council
ID : MR/P027873/1
Pays : United Kingdom

Commentaires et corrections

Type : UpdateOf
Type : UpdateIn

Informations de copyright

Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Références

Trans R Soc Trop Med Hyg. 1988;82(4):645-6
pubmed: 3256125
Trans R Soc Trop Med Hyg. 2008 Aug;102(8):811-6
pubmed: 18579169
Malar J. 2018 Aug 17;17(1):298
pubmed: 30119666
J Clin Epidemiol. 2011 Apr;64(4):380-2
pubmed: 21185693
BMC Public Health. 2018 Jul 18;18(1):894
pubmed: 30021543
Parasit Vectors. 2013 Mar 07;6:57
pubmed: 23497471
Br Med J. 1900 Sep 29;2(2074):949-51
pubmed: 20759182
PLoS Negl Trop Dis. 2010 Aug 03;4(8):e773
pubmed: 20689815
Acta Trop. 2018 May;181:84-94
pubmed: 29452110
Cochrane Database Syst Rev. 2020 Oct 15;10:CD013398
pubmed: 33058136
Rev Venez Sanid Asist Soc. 1960 Dec;25:55-60
pubmed: 13868426
Trials. 2008 Jun 06;9:33
pubmed: 18538004
PLoS One. 2019 Jan 10;14(1):e0210408
pubmed: 30629648
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Am J Trop Med Hyg. 2007 Dec;77(6):1020-7
pubmed: 18165515
PLoS Negl Trop Dis. 2020 Jan 16;14(1):e0007831
pubmed: 31945061
J Clin Epidemiol. 2013 Feb;66(2):151-7
pubmed: 22542023
Malar J. 2014 Aug 23;13:330
pubmed: 25149656
Lancet Planet Health. 2018 Nov;2(11):e498-e508
pubmed: 30396441
Trends Parasitol. 2016 Mar;32(3):187-196
pubmed: 26826784
Lancet. 2019 Apr 13;393(10180):1517-1526
pubmed: 30878222
Int J Epidemiol. 2013 Feb;42(1):235-47
pubmed: 23396849
Malar J. 2013 Mar 16;12:99
pubmed: 23497325
Stat Med. 2006 Oct 30;25(20):3443-57
pubmed: 16345038
Malar J. 2013 Sep 12;12:319
pubmed: 24028542
Trials. 2016 Jun 03;17(1):275
pubmed: 27255167
Sci Rep. 2019 May 23;9(1):7770
pubmed: 31123317
Malar J. 2003 Dec 10;2(1):45
pubmed: 14667242
Bull World Health Organ. 2000;78(9):1078-92
pubmed: 11019457
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Lancet Planet Health. 2017 Aug;1(5):e188-e199
pubmed: 29851640
PLoS One. 2016 Jul 12;11(7):e0158331
pubmed: 27403877
Malar J. 2015 Jun 09;14:209
pubmed: 26055986
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
BMC Infect Dis. 2017 Sep 22;17(1):639
pubmed: 28938876
Malar J. 2016 Sep 01;15(1):447
pubmed: 27586055
Malar J. 2018 Feb 27;17(1):96
pubmed: 29482556
Asian Pac J Trop Med. 2013 Jan;6(1):61-7
pubmed: 23317888
Malar J. 2018 Aug 20;17(1):302
pubmed: 30126462
Lancet Infect Dis. 2005 Nov;5(11):695-708
pubmed: 16253887
Malar J. 2015 Aug 14;14:314
pubmed: 26268225
Lancet. 2009 Sep 19;374(9694):998-1009
pubmed: 19732949
PLoS Med. 2017 Feb 21;14(2):e1002234
pubmed: 28222094
PLoS Med. 2012 Jan;9(1):e1001165
pubmed: 22303287
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12081-6
pubmed: 26324912
Am J Trop Med Hyg. 2018 Dec;99(6):1475-1484
pubmed: 30350770
Am J Trop Med Hyg. 2009 Dec;81(6):944-9
pubmed: 19996421
J Med Entomol. 2009 May;46(3):505-10
pubmed: 19496420

Auteurs

Joanna Furnival-Adams (J)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Evelyn A Olanga (EA)

Malaria Alert Centre of the College of Medicine, Blantyre, Malawi.

Mark Napier (M)

Council for Scientific and Industrial Research, Pretoria, South Africa.
Centre for Development Support, University of the Free State, Bloemfontein, South Africa.

Paul Garner (P)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH